| Name | Title | Contact Details |
|---|
American Shared Hospital Services is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orthocare Medical Eqp is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow`s footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care.
MicroBioLogics is a Saint Cloud, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a startup up medical device company whose sole focus and mission are to transform patient care through innovative Med-tech solutions. Our initial product is a minimally invasive Prostate Volume Measurement Device to help doctors evaluate a patient`s prostate health. Our solution includes a controller that receives measurement data from an encoder device. The encoder a disposable, single-use component made with an injection molding process. We are in the proof of concept phase and want to move to test marketing trials and production by end of 2020.